Anti-CD4 Antibody, PE-Labeled
This anti-CD4 antibody is a purified recombinant antibody, which is labeled with R-Phycoerythrin (PE). This antibody has been tested by flow cytometry for specific binding to human CD4 on the surface of PBMCs (BPS Bioscience #79059).
≥90%
8 mM Phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, 0.09% Sodium Azide, 0.2% BSA, and up to 20% glycerol. May contain a protein stabilizer.
PE is an oligomeric protein complex (270 kDa) from red algae that exhibits intensely bright red-orange fluorescence with excitation peak at 566 nm and an emission peak at 574 nm. The complex consists of six heterodimers, α subunit (18 kDa) and β-subunit (20 kDa), and an additional γ-subunit (34 kDa).
CD4 (cluster of differentiation 4) is part of the immunoglobulin superfamily, and is found in T-helper cells, monocytes, macrophages and dendritic cells. It is a co-receptor in the TCR (T-cell receptor), binding to MHC (major histocompatibility complex) class II molecules. CD4 binds to the tyrosine kinase Lck (lymphocyte-specific protein tyrosine kinase), which can phosphorylate the ITAM (immunoreceptor tyrosine activation motifs) domain of the CD3, activating CD3-related signaling. CD4 is a typical T cell marker of T helper cells, and it has been linked to cancer, autoimmune diseases such as vitiligo and type I diabetes. In addition, HIV-1 makes use of CD4 to trigger viral envelope protein conformational changes that allow cell infection. Ibalizumab, an anti-CD4 antibody, is currently used in the treatment of HIV, being considered a first-in-class medication. Further studies into CD4 and potential strategies around it may benefit patients and CD4 related diseases.